BidaskClub cut shares of Endologix (NASDAQ:ELGX) from a buy rating to a hold rating in a research note issued to investors on Friday morning.

Other equities research analysts have also issued reports about the stock. Canaccord Genuity reiterated a hold rating and set a $5.00 target price on shares of Endologix in a research note on Monday, October 9th. Stifel Nicolaus set a $6.00 target price on shares of Endologix and gave the company a hold rating in a research note on Friday, October 6th. Royal Bank of Canada reiterated a hold rating and set a $5.00 target price on shares of Endologix in a research note on Tuesday, October 3rd. Piper Jaffray Companies reiterated an overweight rating on shares of Endologix in a research note on Tuesday, December 12th. Finally, ValuEngine lowered shares of Endologix from a sell rating to a strong sell rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $5.41.

Shares of Endologix (ELGX) opened at $5.25 on Friday. The company has a debt-to-equity ratio of 2.61, a current ratio of 2.90 and a quick ratio of 2.11. Endologix has a 12 month low of $4.08 and a 12 month high of $7.66.

Several large investors have recently bought and sold shares of ELGX. Kopp Investment Advisors LLC increased its stake in shares of Endologix by 11.5% in the 2nd quarter. Kopp Investment Advisors LLC now owns 21,950 shares of the medical instruments supplier’s stock worth $107,000 after purchasing an additional 2,270 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Endologix in the 2nd quarter worth $111,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Endologix in the 2nd quarter worth $142,000. Valeo Financial Advisors LLC purchased a new stake in shares of Endologix in the 3rd quarter worth $163,000. Finally, UBS Asset Management Americas Inc. increased its stake in shares of Endologix by 128.1% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 34,898 shares of the medical instruments supplier’s stock worth $170,000 after purchasing an additional 19,600 shares in the last quarter.

WARNING: “BidaskClub Lowers Endologix (ELGX) to Hold” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/bidaskclub-lowers-endologix-elgx-to-hold/1771090.html.

About Endologix

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.